TACE联合阿帕替尼治疗中晚期原发性肝癌的临床疗效分析  

Clinical efficacy of apatinib combined with TACE on treatment of primary liver cancer

作　　者：徐勤 高珊 缪继东[1] 宋怡兵[1] XU Qin1,GAO Shan2,MIAO Jidong1,SONG Yibing1(1. Department of Oncology, Zigong Fourth People＇s Hospital, Zigong 643000, Sichua, China; 2. Department of Otolaryngology, Zigong Fourth People＇ s Hospital, Zigong 643000, Sichua, Chin)

机构地区：[1]自贡市第四人民医院肿瘤科,四川自贡643000 [2]自贡市第四人民医院耳鼻喉科,四川自贡643000

出　　处：《西部医学》2018年第5期744-747,共4页Medical Journal of West China

摘　　要：目的观察中晚期原发性肝癌(hepatocellular carcinoma,HCC)患者应用经皮肝动脉介入化疗栓塞术(transcatheter arterial chemoembolization,TACE)后联合使用阿帕替尼的临床疗效,并与联合索拉非尼进行对比。方法将42例中晚期原发性肝癌患者分为两组,介入化疗栓塞加阿帕替尼联合治疗(实验组)及介入化疗栓塞加索拉非尼联合治疗(对照组)各21例,对两组间临床疗效、AFP、不良反应进行分析比较。结果实验组客观缓解率、疾病控制率、1年生存率与对照组相比差异无统计学意义(P>0.05);两组间不良反应比较,实验组出现高血压、皮肤粘膜反应高于对照组,差异有统计学意义(P<0.05),不良反应经对症处理后均缓解;治疗后3月两组甲胎蛋白均较治疗前明显下降,差异有统计学意义(P<0.05),实验组甲胎蛋白下降幅度与对照组相比差异无统计学意义(P>0.05)。结论肝动脉介入化疗栓塞术后联合使用阿帕替尼或索拉非尼治疗中晚期原发性肝癌,其临床获益率均较高,可明显降低甲胎蛋白,不良反应可控,值得临床推广应用。Objective To observe the clinical efficacy in patients with middle-advanced primary liver cancer treated with TACE combined with apatinib.Methods 42 patients with the middle-advanced primary liver cancer were divided into the treatment group（apatinib combined with TACE）and the control group（sorafenib combined with TACE）.The clinical efficacy,the expression of AFP and adverse reactions were observed.Results No statiscally significant differences were found in ORR,DCR and 1 year survival rate between the two groups（P〉0.05）.The adverse reactions including hypertension,skin mucosal reaction in the treatment group were higher than those in the control group（P〈0.05）.The adverse reactions were relieved after symptomatic treatment.The descent range of AFP 3 month after treatment of the two group was higher than that before treatment（P〈0.05）.While no statistic differences were obtained in the descent range of AFP between the treatment group and the control group（P〉0.05）.Conclusion Apatinib combined with TACE in the treatment of liver cancer is helpful to improve the DCR and decrease the expression of AFP.The clinical efficacy is not inferior to Sorafenib combined with TACE,and it is a good choice for treatment of middle-advanced primary liver cancer.

关 键 词：原发性肝癌 肝动脉插管介入化疗栓塞术 索拉替尼 阿帕替尼 临床疗效 

分 类 号：R735.7[医药卫生—肿瘤]